Treace Medical Concepts, Inc. (TMCI)
TMCINASDAQ-GSMedical/Dental Instruments
$4.89
+0.1050 (+2.20%) today
Regular session, Nov 10, 12:47 PM ET
- Market cap
- $320.26m
- P/E
- –
- EPS, last 4 quarters
- $-0.8300
- Dividend yield
- –
- Day range
- $4.67 to $5.15
- 52-week range
- $1.17 to $5.25
- Average volume
- 245.9k
- Previous close
- $4.78
Analysts
3 coveringHold1 buy, 2 hold, 0 sell
Targets a year out average $6.50, +33.1% from here
Earnings
next estimate $-0.0500Next report
Dec 2025
+20.0%
Mar 2026
+9.7%
Jun 2026
+20.0%
Sep 2026
+26.9%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $50.21m | $62.52m | $47.20m | $45.38m |
| Gross profit | $39.71m | $50.40m | $37.41m | $35.61m |
| Operating income | -$15.68m | -$5.92m | -$17.17m | -$14.96m |
| Net income | -$16.29m | -$9.39m | -$17.96m | -$15.87m |
Last four quarters: revenue $205.31m, margin -29.0%, free cash flow -$25.05m
News
8 latest- Stifel Upgrades Treace Medical Concepts to Buy from HoldFintel · 1 day ago
- What Treace Medical Concepts (TMCI) Said on Its Q3 Earnings CallMarketBeat · 4 days ago
- Treace Medical (TMCI) Q3 2026 Earnings Call TranscriptThe Motley Fool · 4 days ago
- Treace Medical Concepts, Inc. Reports Third Quarter 2026 Financial ResultsFintel · 4 days ago
- Treace Medical Concepts, Inc Q3 Loss Narrows RTTNews · 4 days ago
- Treace Medical Concepts (TMCI) Reports Q3 Loss, Tops Revenue EstimatesZacks · 4 days ago
- Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Beats Revenue EstimatesZacks · 5 days ago
- UFP Technologies (UFPT) Q3 Earnings and Revenues Surpass EstimatesZacks · 7 days ago
The company
Treace Medical Concepts, Inc. is a medical technology company with the goal of being the recognized leader in the surgical treatment of bunions and other foot & ankle conditions. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty 3D Bunion Correction System - a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- treace.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.